Formulation of Modified Liquid-Solid Compact for Dissolution Enhancement of Raloxifene Hydrochloride.
Raloxifene hydrochloride (RLX), used in postmenopausal osteoporosis, is a class-II drug as per Biopharmaceutics Classification System. The purpose of this research was to formulate modified liquisolid compacts (MLSC) of RLX for improved dissolution in immediate-release tablet formulations. Prelimina...
| Publicado en: | Pharmaceutical Technology Europe Vol. 33; no. 7; pp. 20 - 25 |
|---|---|
| Autores principales: | , , , |
| Formato: | Journal Article |
| Publicado: |
MJH Life Sciences
Jul2021
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=151463016&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 151463016 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 17537967 5NG jtl: Pharmaceutical Technology Europe issn: 17537967 maglogo: N pubinfo: dt: Jul2021 vid: 33 iid: 7 pid: 54670 pub: MJH Life Sciences place: Cranbury, New Jersey artinfo: ui: 151463016 151463016 ppf: 20 ppct: 5 formats: fmt: @attributes: type: P tig: atl: Formulation of Modified Liquid-Solid Compact for Dissolution Enhancement of Raloxifene Hydrochloride. aug: au: Patel, Gayatri Pandya, Dharmang Gandhi, Pushti Parikh, Rajesh affil: Research Scholar, all at Charotar University of Science and Technology, Ramanbhai Patel College of Pharmacy, Department of Pharmaceutics & Pharmaceutical Technology, CHARUSAT Campus, Changa-388421, Gujarat, India sug: ab: Raloxifene hydrochloride (RLX), used in postmenopausal osteoporosis, is a class-II drug as per Biopharmaceutics Classification System. The purpose of this research was to formulate modified liquisolid compacts (MLSC) of RLX for improved dissolution in immediate-release tablet formulations. Preliminary trials on selection of excipients were performed. Fourier transform infrared spectra illustrated no interaction between drug and MLSC powder. The X-ray diffraction studies demonstrated the transformation of the crystalline nature of drug into partial amorphous state in MLSC. After all experimental results on selection of excipients were analyzed, the final tablet formulation was derived and manufactured. The results of an in-vitro drug release study from the selected batch illustrated a remarkable improvement in the dissolution rate as compared to reference product. An accelerated stability study as per the ICH Q1 (R2) guideline of the optimized batch was performed for six months and showed no significant change in critical quality attributes of formulation. pubtype: Trade Publication doctype: Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|